Presentations

AACR

• TRPH-222, a Novel Anti-CD22 Antibody Drug Conjugate (ADC), Has Significant Anti-Tumor Activity in NHL Xenografts and Reduces B-Cells in Monkeys; Apr 14-18, 2018 – poster

ASH

• TRPH-222, a Novel Anti-CD22 Antibody Drug Conjugate (ADC), Has Significant Anti-Tumor Activity in NHL Xenografts and is Well Tolerated in Non-Human Primates; Dec 9-12, 2017 – poster

ASCO:

• Phase 1, Multicenter, Open-Label, Dose-Escalation Study of Marizomib (MRZ) and Bevacizumab (BEV) in WHO Grade IV Malignant Glioma (G4 MG); June 3-7, 2016 – poster

AACR:

• Investigation of Pharmacodynamic and Predictive Biomarkers to Define Response to Proteasome Inhibitor Marizomib in Glioma; April 16-20, 2016 – poster

SNO:

• Marizomib for Glioblastoma, Nov 16-19, 2016 – oral presentation

SNO

• Targeting Proteasome Activity with Marizomib as a Therapeutic Perspective for Glioma Patients. The 20th Annual Society for Neuro-Oncology; Nov 19-22, 2015 – poster

AACR

• Marizomib (NPI-0052) Activity as a Single Agent in Malignant Glioma. The Annual American Association for Cancer Research; April 5-9, 2014 – poster

ASH:

• PMD-107: Marizomib, Pomalidomide and Low-dose Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase 1, Multicenter, Open Label Study; Dec 3-6, 2016 – poster
• Marizomib for CNS-Multiple Myeloma; Dec 3-6, 2016 – poster

ASH:

• Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ), and Low-Dose Dexamethasone (Lo-DEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) – Preliminary Study Results. The 57^th American Society of Hematology Annual Meeting; Dec 4-7, 2015 – poster
• Oral Proteasome Inhibitor Marizomib and IMiD® Imunomodulatory Drug Pomalidomide Trigger Synergistic Anti-Myeloma Activity and Enhanced Proteasome Inhibition In Vitro and In Vivo. The 57^th Annual American Society of Hematology; Dec 4-7, 2015 – poster

IMW:

• Phase 1, Multicenter, Open-label, Dose-escalation, Combination Study of Pomalidomide (POM), Marizomib (MRZ), and Dexamethasone (Lo-Dex) in Patients with Relapsed and Refractory Multiple Myeloma: Study NPI-0052-107. The 15^th Annual International Myeloma Workshop; Sept 23-26, 2015 – oral presentation
• Phase 1, Dose-Escalation Study of Marizomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: NPI-0052-101 Part 1 – Final Results. The 15^th International Myeloma Workshop; Sept 23-26, 2015– poster
• Phase 1 Clinical Trial of Marizomib in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 – Final Results. The 15^th Annual International Myeloma Workshop; Sept 23-26, 2015– poster

ASH:

• Synergistic Anti-Myeloma Activity of a Proteasome Inhibitor Marizomib and IMiD® Immunomodulatory Drug Pomalidomide. The 56^th Annual American Society of Hematology; Dec 6-9, 2014 – poster

ASCO:

• Combination of proteasome inhibitor marizomib and immunomodulatory agent pomalidomide trigger synergistic cytotoxicity in multiple myeloma. The 50^th Annual American Society of Clinical Oncology; May 30 – June 4, 2014 – poster

AACR:

• A Production-Scalable Cabazitaxel Cellulose Nanoparticle Exhibits Significant Efficacy in a Bone Model of Docetaxel-Resistant Prostate Cancer; April 16-20, 2016 – poster